Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week Low – Here’s Why

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $665.04 and last traded at $666.41, with a volume of 31218 shares changing hands. The stock had previously closed at $672.98.

Analysts Set New Price Targets

REGN has been the topic of a number of recent analyst reports. Citigroup cut their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. TD Cowen cut their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday. Bernstein Bank lowered their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday. Finally, BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $983.65.

Regeneron Pharmaceuticals Trading Up 4.5 %

The firm has a market capitalization of $76.60 billion, a price-to-earnings ratio of 17.25, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The firm’s 50 day moving average is $719.16 and its 200 day moving average is $918.90. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the business earned $11.86 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.75 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.50%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently made changes to their positions in REGN. International Assets Investment Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $127,489,000. KBC Group NV lifted its position in shares of Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after purchasing an additional 102,198 shares in the last quarter. Icon Wealth Advisors LLC grew its position in Regeneron Pharmaceuticals by 18,342.0% during the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after purchasing an additional 75,569 shares in the last quarter. Finally, State Street Corp increased its stake in Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after buying an additional 61,277 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.